Company: JUNS
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010990
Chunk: 51

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 8
Chunk 51
---
 a validated mouse model of Parkinson’s
Disease (PD) at the University of Miami in 2021. The model of Parkinson’s Disease that was
used in this preclinical study mimics many aspects of the disease utilizing a unilateral injection of a neurotoxin precursor that elicits
nigral cell loss, striatal dopamine loss and behavior deficits similar to physiological characteristics of human disease.

We believe that
results from this preclinical study indicate that Parkinson’s Disease might be the best target for treatment and financial opportunity
among the multiple indications where JOTROL might play a role. The Company is now in the process of planning its first Phase II clinical
trial in a patient population. This will be a Phase IIa study conducted with the assistance of Zina Biopharmaceuticals that is led by
Dr. Charbel Moussa, MBBS,Ph.D. The study is expected to start in the third quarter of 2025 and have results available approximately 12
months thereafter.

We are also targeting the treatment of MCI/early
Alzheimer’s Disease. We received funding of $2.2 million from the National Institute of Aging (“NIA”) in in 2020 and
2022 from a grant application for a Phase 1 study for Mild Cognitive Impairment/ Alzheimer. In the NIA scientific review summary
statement of our Phase I study application, it is stated that the NIA is looking forward to a Phase II study with an enhanced resveratrol
product, based on the earlier study results from the well published Turner et al. Alzheimer’s study.

In October 2024, we submitted an application for a $16.5 million grant
from the NIA for a Phase II trial in MCI/early Alzheimer’s Disease. In May 2025, we learned that the application will not be approved.
Therefore, studies focused on this indication will be paused until we receive biomarker results from our Phase 2a in Parkinson’s
Disease. We expect that several of those biomarkers, particularly in cognition, will be used to further validate the use of JOTROL in
Alzheimer’s Disease. This will enable us to determine the best path forward in MCI/early Alzheimer’s Disease.

24

We have recently entered into service agreements
in the areas of Business Development, CMC (Chemistry, Manufacturing, and Controls), regulatory affairs and clinical trial management with
companies that has their main operation in Hong Kong. These agreements are with companies that